Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin versus escitalopram for major depressive disorder
ISRCTN10584863Phase 2Completed
- Sponsor
- Joint Research Compliance Office
- Start
- Sep 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Psilocybin + placebo with Psilocybin + escitalopram (2 arms). Primary endpoint: Amygdala BOLD response to fearful faces. Started Sep 2018; status: completed.
02
Drugs
psilocybinescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN10584863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10584863.